Loading presentation...

Present Remotely

Send the link below via email or IM


Present to your audience

Start remote presentation

  • Invited audience members will follow you as you navigate and present
  • People invited to a presentation do not need a Prezi account
  • This link expires 10 minutes after you close the presentation
  • A maximum of 30 users can follow your presentation
  • Learn more about this feature in our knowledge base article

Do you really want to delete this prezi?

Neither you, nor the coeditors you shared it with will be able to recover it again.


Wolff- Parkinson-White Syndrome

No description

Marilize Kleynhans

on 26 January 2017

Comments (0)

Please log in to add your comment.

Report abuse

Transcript of Wolff- Parkinson-White Syndrome

Wolff- Parkinson-White Syndrome
Madri Wiid
Marilize Kleynhans
Licia Roberts

Sudden death in young competitive athlete...
Wolf-Parkinson- White Syndrome
Reference list:
1. Wiedermann CJ, Becker AE, Hopferwieser T, Mühlberger V, Knapp E. Sudden death in a young competitive athlete with Wolf—Parkinson—White syndrome. European Heart Journal. 1987 Jun 1;8(6):651-5.
2. Rao AL, Salerno JC, Asif IM, Drezner JA. Evaluation and management of Wolff-Parkinson-White in athletes. Sports Health: A Multidisciplinary Approach. 2014 Jul 1;6(4):326-32.
3. Gollob MH, Green MS, Tang AS, Gollob T, Karibe A, Hassan AS, Ahmad F, Lozado R, Shah G, Fananapazir L, Bachinski LL. Identification of a gene responsible for familial Wolff–Parkinson–White syndrome. New England Journal of Medicine. 2001 Jun 14;344(24):1823-31.
4. Medscape[Internet]. Wolff-Parkinson-White Syndrome Treatment & Management. Available from: http://emedicine.medscape.com/article/159222-treatment#d1
5. Lu CW, Wu MH, Chen HC, Kao FY, Huang SK. Epidemiological profile of Wolff–Parkinson–White syndrome in a general population younger than 50years of age in an era of radiofrequency catheter ablation. International journal of cardiology. 2014 Jul 1;174(3):530-4.
6.Walker BR, Colledge NR, Ralston SH, Penman ID. Davidson’s Principles and Practice of Medicine. 22nd ed. Edinburgh:Elsevier; 2014

Treatment options:
Catheter ablation of the accessory atria-ventricular pathways by radio-frequency current.
Pharmacotherapy includes antiarrhythmic agents for example: Beta-blockers, Flecainide, Propafenone, Amiodarone etc.
Digoxin and Verapamil appears to be contraindicated for many patients with Wolff-Parkinson-White syndrome because it may enhance antegrade conduction through the accessory pathway.

Why is WPW syndrome such a big deal?

A young athlete suddenly died after being discharged ouf of hospital 10 days earlier. He was admitted earlier for rapid heart beating and left the hospital in a stable condition.

His history stated that he was asymptomatic and occasionally experienced tachycardias.
His ECG showed a short PR interval as well as a Delta wave pattern in the QRS-complex.

Conducting tissue in the heart
SA node
AV node
Bundle of His
Left and right bundle
Purkinje fibres
WPW syndrome is a birth defect where an accessory conducting pathway is formed.

In a normal heart electrical impulses flow from the SA node - AV node- Bundle of His- L/R bundle branches - Purkinje fibres.
But due to the accessory pathway a short circuit is is created which can exclude the AV node and lead to the pre-excitation of the ventricles.
Wolff-Parkinson-White Syndroem can lead to:
Heart failure
Sudden cardiac death
There are three different types known.
WPW: Sinus rhythm.
The accessory pathway and the AV node both depolarizes the ventricles - thus there is a sinus (regular) heart beat. Although pre-excitation via the accessory band can create the very distinct ECG pattern: a short PR interval and the delta wave in the QRS-complex.
WPW: Orthodromic Tachycardia:
The electrical impulse moves in the normal direction through the AV node but uses the accessory pathway to return to the atria. This can lead to tachycardia.
WPW Atrial Fibrillation:
Ventricles are mainly depolarized via the accessory pathway. This is very dangerous as the accessory pathway does not posses rate-limiting properties. And can lead to tachycardia, syncope, collapse and death.

The prevalence of WPW is 0.68-1.7/1000 globally, but there is a 1.5-3.1/1000 prevalence in Western Countries.

There is a peak in the ages 20-24 years.

The prevalence of Sudden Cardiac Death in symptomatic patients is 0.25% per year or a 3-4% in a lifetime.
Main research and development issues raised by WPW.
Research about treatment options is difficult because some patients' first presentation of WPW syndrome is ventricular fibrillation or Sudden Cardiac Death.
50% of patients with WPW syndrome is asymptomatic.
The ECG pattern varies from person to person and may even appear normal in some individuals.
WPW syndrome is a rare congenital heart disorder and thus not much research could have been done.
The genetic cause of WPW is not yet well understood.
Catheter Ablation:
Full transcript